Dr. Jason Westin on Combination Targeted Therapy Prior to Chemotherapy for DLBCL

News
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.

Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
5 experts in this video
Related Content
EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Tim Cortese
June 3rd 2025
Article

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

Kristi Rosa
June 3rd 2025
Article

Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 3rd 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Less Inflammatory Diets Associated with Improved OS in Stage III Colon Cancer

Less Inflammatory Diets Associated with Improved OS in Stage III Colon Cancer

Bridget Hoyt
June 3rd 2025
Article

Data suggest that anti-inflammatory diets and regular physical activity are associated with improved overall survival in patients with stage III resected colon cancer.